SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001737287-21-000022
Filing Date
2021-05-05
Accepted
2021-05-05 16:24:09
Documents
62
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q allo-20210331.htm   iXBRL 10-Q 1373911
2 EX-31.1 allo-20210331xex311.htm EX-31.1 9877
3 EX-31.2 allo-20210331xex312.htm EX-31.2 9899
4 EX-32.1 allo-20210331xex321.htm EX-32.1 7102
  Complete submission text file 0001737287-21-000022.txt   6057245

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT allo-20210331.xsd EX-101.SCH 42123
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT allo-20210331_cal.xml EX-101.CAL 63652
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT allo-20210331_def.xml EX-101.DEF 247112
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT allo-20210331_lab.xml EX-101.LAB 550159
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT allo-20210331_pre.xml EX-101.PRE 347100
10 EXTRACTED XBRL INSTANCE DOCUMENT allo-20210331_htm.xml XML 933931
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

IRS No.: 823562771 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38693 | Film No.: 21893728
SIC: 2836 Biological Products, (No Diagnostic Substances)